Details for: JANUVIA
Company: MERCK CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02388839 | JANUVIA | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) | 25 MG | TABLET | ORAL |
| 02388847 | JANUVIA | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) | 50 MG | TABLET | ORAL |
| 02303922 | JANUVIA | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) | 100 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) inhibitors - Assessing the risk of joint pain (arthralgia)
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure
Summary Safety Review - DPP-4 inhibitors (gliptins) - Assessing the Potential Risk of Gastrointestinal Blockage (Gastrointestinal Obstruction)
Summary Safety Review - Incretin-Based Therapies - Assessing the Potential Risk of Pancreatic Cancer
Summary Safety Review - Dipeptidylpeptidase-4 inhibitors - Assessing the potential risk of a skin reaction (bullous pemphigoid)
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) inhibitors - Assessing the risk of joint pain (arthralgia)
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure
Summary Safety Review - DPP-4 inhibitors (gliptins) - Assessing the Potential Risk of Gastrointestinal Blockage (Gastrointestinal Obstruction)
Summary Safety Review - Incretin-Based Therapies - Assessing the Potential Risk of Pancreatic Cancer
Summary Safety Review - Dipeptidylpeptidase-4 inhibitors - Assessing the potential risk of a skin reaction (bullous pemphigoid)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.